Enabling proactive healthcare
PromarkerEso is blood test that detects specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma in your patients with chronic reflux.
The blood test designed to rule out EAC for those suffering chronix reflux
Esophageal Adenocarcinoma (EAC) Detection
WHAT’S THE DIFFERENCE
THE GOLD
STANDARD
Endoscopy with Biopsy
- Invasive
- Expensive (ref)
- Procedural risk of injury
- Risk of missed dysplasia
- Multidisciplinary team
- Endoscopy limited by health system capacity
Biomarker blood test
- Simple blood collection
- Inexpensive (ref)
- No surgical biopsy
- High accuracy (Sn/Sp)
- Pathology test + result
- Easy access blood test
Clinical Studies & Collaborations
The PromarkerEso test was developed and validated in serum samples from three independent cohorts:
- PROBE-NET (N=103): The Progression of Barrett’s Esophagus to Cancer Network, Australia
- Ochsner (N=24): United States
- VCB (N=165): Victorian Cancer Biobank, Australia
PromarkerEso demonstrated an excellent discrimination performance (AUC-ROC: 0.82-0.93)
Rule out EAC, manage their chronic reflux with confidence
- PromarkerEso’s specificity of 98.9% provides high EAC “rule out” confidence, which far exceeds the 87% achieved by endoscopy
- Patients can avoid unnecessary and costly endoscopy and biopsy procedures
- With a sensitivity of 91.4%, PromarkerEso is much better at identifying Esophageal Adenocarcinoma compared to just 75% for endoscopy.
- Therapy for these patients can be better targeted
FAQs
If you need further assistance, information or support, our team is here to help, please email us.
Who can be tested with PromarkerEso?
The test is indicated for adults with no prior cancer diagnosis who exhibit at least two risk factors for EAC, including:
• Heartburn or Acid Reflux (also known as GastroEsophageal Reflux Disease (GERD))
• Age > 50 years
• Overweight (BMI > 25 kg/m²)
How do I test my patients with PromarkerEso?
PromarkerEso is now available in Australia. Please contact us to request this test for your practice, or to learn when this test will be available in your market
When will the test be available?
The test is now available in Australia and will be introduced to other markets as regulatory approvals are received. Please CONTACT US for availability in your region.
How do I manage my patients identified as Low Risk by PromarkerEso?
Continue managing their chronic reflux, but without the immediate concern for the presence of EAC.
What can be done for patients identified as MODERATE or HIGH RISK by PromarkerEso?
Follow-up with upper GI endoscopy will be advised. Further management will be determined based on endoscopic examination and any biopsy conducted. To obtain a detailed PromarkerEso interpretation guide, CLICK HERE
How does PromarkerEso work and what does it measure?
PromarkerEso is a non-invasive, multi-biomarker and clinical factor blood test intended to identify the risk of esophageal adenocarcinoma (EAC) in the presence of chronic reflux
The PromarkerEso test consists of two elements:
i. A serum sample analysis to measure the concentration of a panel of four glycoprotein biomarkers by mass spectrometry; and
ii. A validated cloud-based software algorithm for processing the laboratory test results with clinical variables to determine EAC risk.
How accurate is PromarkerEso in diagnosing patients risk category of developing disease?
The PromarkerEso test score provides the probability of having EAC from 0-100% defined as:
• Low Risk (probability score <20%)
• Moderate Risk (probability score 20%-75%)
• High Risk (probability score >75%)
Test cut-off points were prospectively selected in clinical studies to optimise test performance. The Low/Moderate cut-off provides optimal sensitivity to increase true positives, while the Moderate/High cut-off provides optimal specificity to reduce false positives. Clinical validation studies demonstrate PromarkerEso test performance as a Sensitivity of 91.4%, and a Specificity of 98.9%, resulting in a Negative Predictive Value of 99.9% for EAC.
How long does it take to receive PromarkerEso test results?
The PromarkerEso test result will be available within two weeks from blood collection.
Take the next step to proactive management of your patients’ chronic reflux risks
Bring the power of esophageal cancer detection to your practice. PromarkerEso can detect specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma in your patient, allow
